Search clinical trials for: F61 Placebo

Total 53914 results

Wuhan Institute of Biological Products Co., Ltd

Not yet recruiting

Clinical Study of F61 Injection in Healthy Chinese Subjects

COVID-19
Vertex Pharmaceuticals Incorporated

Recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Ireland, United Kingdom
Taisho Pharmaceutical R&D Inc.

Completed

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 2

Narcolepsy Type 2

Spain, United States, Japan, Italy, France, Germany, Australia, Netherlands, Finland, Norway, Sweden, Switzerland
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 1

Narcolepsy Type 1

Spain, Japan, France, Germany, United States, Norway, Netherlands, Finland, Switzerland, Australia, Italy, Sweden
Symic OA Co.
Nordic Bioscience A/S

Completed

A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee (MODIFY2)

Osteoarthritis

Estonia
Boehringer Ingelheim

Completed

Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers

Healthy
MyoKardia, Inc.

Completed

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM)

Obstructive Hypertrophic Cardiomyopathy

United States, France, Germany, Czechia, Spain, Belgium, Denmark, Portugal, Netherlands, Israel, Poland, United Kingdom, Italy
Nido Biosciences, Inc.

Recruiting

A Study of NIDO-361 in Patients With SBMA (PIONEER KD)

Spinal and Bulbar Muscular Atrophy | Kennedy's Disease

Korea, Republic of, Denmark, Italy, United Kingdom
Teijin Pharma Limited

Completed

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR) (J-REPAIR)

Acute Ischemic Stroke

Japan
Symic OA Co.
Nordic Bioscience Clinical Development

Completed

A Trial of SB-061 in Osteoarthritis of the Knee (MODIFY-OA)

Osteoarthritis

Estonia
Akros Pharma Inc.
ICON Clinical Research

Recruiting

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (POWER-HF)

Chronic Heart Failure

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
MyoKardia, Inc.

Completed

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) (MAVERICK-HCM)

Non-obstructive Hypertrophic Cardiomyopathy

United States
Boehringer Ingelheim

Completed

Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL

Healthy
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Kowa Research Institute, Inc.

Completed

A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease

Dry Eye Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Cystic Fibrosis

United States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
Kezar Life Sciences, Inc.

Recruiting

KZR-261 in Subjects With Advanced Solid Malignancies

Advanced/Metastatic Solid Tumor

United States
MyoKardia, Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers

Healthy

Australia
MyoKardia, Inc.

Completed

Single Ascending Dose Study of MYK-461 in Healthy Volunteers

Healthy

United Kingdom
Kowa Research Institute, Inc.

Completed

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

Dry Eye Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Presidio Pharmaceuticals, Inc.

Completed

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Chronic Genotype 1 Hepatitis C Virus Infection

United Kingdom, Denmark, United States
Vivasure Medical Limited

Completed

Safety and Performance Study of Large Hole Vascular Closure Device FIV (Frontier-IV)

Percutaneous CFA Arteriotomy Closure

Ireland, Germany
Amgen

Terminated

AMG 761 in Adults With Asthma

Asthma

United States
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Cystic Fibrosis

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM)

Cardiomyopathy, Hypertrophic

Spain, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, Israel, Japan, Netherlands, Norway, Poland, Portugal, United Kingdom, United States, Australia, China, Czechia, India, Italy, Korea, Republic of
LianBio LLC

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Obstructive Hypertrophic Cardiomyopathy

China
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Completed

CP-461 for the Treatment of Crohn's Disease

Crohn's Disease

United States
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
The Immunobiological Technology Institute (Bio-Manguinhos)...
Oswaldo Cruz Institute

Not yet recruiting

Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

Leprosy

Brazil
Ipsen

Completed

Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia

Friedreich Ataxia

France
Ipsen

Completed

A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints

Retention Disorders, Cognitive | Memory Disorders, Age-Related

France
US Department of Veterans Affairs

Completed

Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis

Multiple Sclerosis | Cognitive Ability, General

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria

Search clinical trials for: F61 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations